BI-1206
Based on 1 Customer Validation
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL).
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96.82%
- 分子量:143.68 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Human IgG1 lambda
Human
Fc gamma RIIB/CD32b
BI-1206 (5 μg/mL, 0-5 h) blocks Rituximab (5 μg/mL)-induced and Rituximab-based combination with Ibrutinib or Venetoclax or CHOP-induced CD20 internalization effectively in JeKo-1 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
BI-1206 (10 mg/kg, i.v., twice a week) inhibits tumor growth when combined with Rituximab in Rituximab-Ibrutinib-CAR T-triple resistant MCL PDX (PDX-B) NSG mice model[1].
BI-1206 (10 mg/kg, i.v., twice a week for 14 d) has better efficacy and prolonged survival in the triple combination group with Ibrutinib or Venetoclax compared to dual combinations without BI-1206 in JeKo-1 CDX mice model[1].
BI-1206 (10 mg/kg, i.v., twice a week) shows superior anti-tumor activity and prolonged survival when combined with Venetoclax compared to any single or dual combination in Ibrutinib-Rituximab-Venetoclax triple-resistant MCL PDX (PDX-C) model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Ibrutinib-Venetoclax dual resistant MCL PDX (PDX-A) NSG mice model[1]
-
Dosage:10 mg/kg, twice a week
-
Administration:Intravenous injection (i.v.)
-
Result:Reduced percentage of MCL tumor cells (CD5+CD20+) in spleen, liver, bone marrow, and peripheral blood collected from PDX-A mice model.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
ELISA, FACS, Functional assay
-
Immobilized hu-Fcgamma RIIB/C (CD32b/c)-C-his can bind BI-1206. The EC50 for this effect is 27.61 ng/mL.
化学情報
-
性状 Liquid
-
分子量 143.68 kDa
-
Color Colorless to off-white
-
SMILES
[BI-1206]
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
-
データシート (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Powered by Bioz